- Investing.com
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Strategic Overhaul | Explore Kenvue's ambitious "Extraordinary Powers" strategy, aimed at simplifying operations and driving innovation across its diverse product portfolio |
Market Challenges | Delve into Kenvue's response to declining organic sales and regulatory scrutiny, including leadership changes and a comprehensive strategic review |
Brand Powe | Learn how Kenvue leverages its iconic brands like Tylenol and Neutrogena to maintain market leadership despite fierce competition in the consumer health secto |
Financial Outlook | Analyst price targets range from $22 to $29, reflecting varied perspectives on Kenvue's potential for operational improvements and long-term value creation |
Metrics to compare | KVUE | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipKVUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 19.9x | 26.1x | 12.2x | |
PEG Ratio | 0.69 | 0.42 | 0.03 | |
Price/Book | 2.6x | 2.5x | 1.5x | |
Price / LTM Sales | 1.9x | 1.8x | 1.0x | |
Upside (Analyst Target) | 40.0% | 100.3% | 19.2% | |
Fair Value Upside | Unlock | 10.9% | 11.0% | Unlock |